Drug delivery system in treatment against inflammatory bowel disease: present and future

Satohiro Masuda, Yuki Yamamoto

研究成果: ジャーナルへの寄稿記事

抄録

Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate anti-inflammatory drug used as a primary agent to treat inflammatory bowel disease, including ulcerative colitis and to maintain remission in Crohn’s disease. The efficacy of 5-ASA is determined by the degree of drug delivery to the site of inflammation, but it depends on the formulation. In recent years, 5-ASA preparations using drug-delivery system (DDS) technology as a therapeutic agent for ulcerative colitis have been developed one after another, contributing to improvement of therapeutic effect. In this article, we focus on the pharmacokinetic characteristics of each 5-ASA preparation, and introduce the features and clinical usefulness of the preparation.

元の言語英語
ページ(範囲)397-405
ページ数9
ジャーナルDrug Delivery System
33
発行部数5
DOI
出版物ステータス出版済み - 11 25 2018

Fingerprint

Mesalamine
Drug Delivery Systems
Inflammatory Bowel Diseases
Ulcerative Colitis
Therapeutics
Therapeutic Uses
Crohn Disease
Pharmaceutical Preparations
Anti-Inflammatory Agents
Pharmacokinetics
Inflammation
Technology

All Science Journal Classification (ASJC) codes

  • Pharmaceutical Science

これを引用

Drug delivery system in treatment against inflammatory bowel disease : present and future. / Masuda, Satohiro; Yamamoto, Yuki.

:: Drug Delivery System, 巻 33, 番号 5, 25.11.2018, p. 397-405.

研究成果: ジャーナルへの寄稿記事

Masuda, Satohiro ; Yamamoto, Yuki. / Drug delivery system in treatment against inflammatory bowel disease : present and future. :: Drug Delivery System. 2018 ; 巻 33, 番号 5. pp. 397-405.
@article{cd55d0c14fa04c2f9cc8833e7fc591e1,
title = "Drug delivery system in treatment against inflammatory bowel disease: present and future",
abstract = "Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate anti-inflammatory drug used as a primary agent to treat inflammatory bowel disease, including ulcerative colitis and to maintain remission in Crohn’s disease. The efficacy of 5-ASA is determined by the degree of drug delivery to the site of inflammation, but it depends on the formulation. In recent years, 5-ASA preparations using drug-delivery system (DDS) technology as a therapeutic agent for ulcerative colitis have been developed one after another, contributing to improvement of therapeutic effect. In this article, we focus on the pharmacokinetic characteristics of each 5-ASA preparation, and introduce the features and clinical usefulness of the preparation.",
author = "Satohiro Masuda and Yuki Yamamoto",
year = "2018",
month = "11",
day = "25",
doi = "10.2745/dds.33.397",
language = "English",
volume = "33",
pages = "397--405",
journal = "Drug Delivery System",
issn = "0913-5006",
publisher = "Japan Society of Drug Delivery System",
number = "5",

}

TY - JOUR

T1 - Drug delivery system in treatment against inflammatory bowel disease

T2 - present and future

AU - Masuda, Satohiro

AU - Yamamoto, Yuki

PY - 2018/11/25

Y1 - 2018/11/25

N2 - Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate anti-inflammatory drug used as a primary agent to treat inflammatory bowel disease, including ulcerative colitis and to maintain remission in Crohn’s disease. The efficacy of 5-ASA is determined by the degree of drug delivery to the site of inflammation, but it depends on the formulation. In recent years, 5-ASA preparations using drug-delivery system (DDS) technology as a therapeutic agent for ulcerative colitis have been developed one after another, contributing to improvement of therapeutic effect. In this article, we focus on the pharmacokinetic characteristics of each 5-ASA preparation, and introduce the features and clinical usefulness of the preparation.

AB - Mesalazine, also known as mesalamine or 5-aminosalicylic acid (5-ASA), is an aminosalicylate anti-inflammatory drug used as a primary agent to treat inflammatory bowel disease, including ulcerative colitis and to maintain remission in Crohn’s disease. The efficacy of 5-ASA is determined by the degree of drug delivery to the site of inflammation, but it depends on the formulation. In recent years, 5-ASA preparations using drug-delivery system (DDS) technology as a therapeutic agent for ulcerative colitis have been developed one after another, contributing to improvement of therapeutic effect. In this article, we focus on the pharmacokinetic characteristics of each 5-ASA preparation, and introduce the features and clinical usefulness of the preparation.

UR - http://www.scopus.com/inward/record.url?scp=85064738300&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064738300&partnerID=8YFLogxK

U2 - 10.2745/dds.33.397

DO - 10.2745/dds.33.397

M3 - Article

AN - SCOPUS:85064738300

VL - 33

SP - 397

EP - 405

JO - Drug Delivery System

JF - Drug Delivery System

SN - 0913-5006

IS - 5

ER -